It embodies the goodness in powerful, resourceful people collaborating to make a difference in helping people become healthier and feel better in a connected, global environment.
SANTA CLARA, Calif. (PRWEB) October 18, 2017
Simon Chin, CEO of IRIS Biotechnologies Inc. (OTC MKTS:IRSB), and its subsidiary, IRIS Wellness Labs, Inc. was one of five panelists to address the issue “Are DNA and Biomarker Tests Ready for Prime Time?” at the Global Wellness Summit in Palm Beach, Florida. Dr. Kenneth R. Pelletier, PhD, UCSF Clinical Professor of Medicine moderated the panel, which included Dr. Paul Limburg, Medical Director at the Mayo Clinic, and Dr. Elissa Epel, PhD, UCSF Professor of Psychology and Assistant Director of the Center for Health and Community.
Mr. Chin talked about how IRIS was unique in its comprehensive approach, why it is better to analyze both DNA sequence and epigenetics, and the important role microbiome plays in human health and wellness. IRIS is unique in providing comprehensive DNA testing and directly engaging with patients and their physicians while also focusing on disease prevention through life style modification.
At the Summit, Wellness Moonshot was launched with a vision of a “World Free of Preventable Disease”, a call to action to eradicate chronic, preventable diseases by uniting the health and wellness industries. The launch received an enthusiastic response from the 600+ delegates, comprising health and wellness leaders, including Dr. Richard H. Carmona, 17th Surgeon General of the United States, Dr. Mehmet C. Oz, Professor of Surgery, Columbia University, and host, The Dr. Oz Show, and Dr. Dean Ornish, Founder and President, Preventive Medicine Research Institute.
“The time has come to pool our resources - knowledge, access, funding - and use our collective megaphone on the world stage to work towards achieving a world free of preventable disease,” said Susie Ellis, Chairman and CEO of the Global Wellness Summit and Global Wellness Institute.
"The world is increasingly plagued by largely preventable chronic diseases, and the crippling economic burden that comes with them. This call to action is absolutely critical, refocusing on humankind’s most pressing need,” said Dr. Carmona. “The Global Wellness Institute is the right organization to launch this moonshot, as it can only be achieved with high-level collaboration in the many health and wellness sectors.”
The Annual Global Wellness Summit, an invitation-only event, was held at the Breakers Palm Beach Resort in Florida from October 9-11, 2017. Breakers President Paul Leone said that he has witnessed about 15,000 conferences come through the hotel and he can’t think of one that’s more important than the Global Wellness Summit. According to the CDC, approximately 70% of all deaths each year are a result of preventable diseases. The World Economic Forum estimates that the global cost of largely preventable chronic disease could reach $47 trillion by 2030.
At the Global Wellness Summit, Mr. Chin exchanged ideas with many people, including Dr. Michael Roizen, Chief Wellness Officer, Cleveland Clinic. IRIS is the first and only company to offer not only comprehensive DNA testing and integrated, in-depth analysis of the whole person, but also a conference with each client and his or her ordering physician. This physician conference format helps to maintain the patient-physician relationship while introducing cutting-edge genomic science, empowering physicians to deal with health risks uncovered by IRIS's proprietary precision medicine technology. Quicker and better interventions result in cutting costs and saving lives.
In the workplace, IRIS proposes offering every employee a basic wellness program, offering upper level management a complete DNA analysis as well. The DNA analysis benefits the individual directly and his or her family and descendants indirectly in many applications related to health and wellness. Employees who are not offered in-depth DNA analysis may also elect to have a DNA analysis. Either way, IRIS’s wellness program will increase job satisfaction, improve overall health of the employees and reduce absenteeism and job dissatisfaction; the value and return on investment is tremendous.
For the past five years, IRIS CEO, Simon Chin has been serving on the Industrial Advisory Board of the University of Pacific’s Thomas J. Long School of Pharmacy and Health Sciences. Chin has expertise in genomics, big data and precision medicine, and closely follows the trends in the pharmaceutical industry. With two decades of domain expertise in personalized medicine, IRIS is the ideal collaborative partner for many companies to adopt and to innovate healthcare with cutting-edge, patented medical technology. IRIS has foundational patents in an Artificial Intelligence System for Genetic Analysis.
Mr. Chin said, “The Global Wellness Summit is very different from all the conferences I have ever attended. It embodies the goodness in powerful, resourceful people collaborating to make a difference in helping people become healthier and feel better in a connected, global environment.”
About IRIS Biotechnologies Inc.
IRIS Biotechnologies Inc. (OTC MKTS: IRSB) is a life sciences company that develops technologies that provide accurate, affordable precision healthcare through comprehensive analysis of the whole person inside and out. Iris offers the best approach to the treatment of cancer and other diseases through incorporating DNA, RNA and protein analysis with a patient's medical records, family medical history, life style and environmental exposures. Iris enables personalized, cost-effective healthcare and is the future of precision medicine.
About IRIS Wellness Labs, Inc.
Iris Wellness Labs is a private, precision health and wellness company. We work directly with healthy people, patients, physicians, and companies. We provide whole genome sequencing, gene expression testing, and microbiome testing. We work with genetic counselors, and psychologists. We collect information, do the research and analyze genomics, gene expression, protein expression, life style, environment, and comprehensive family medical history to understand the whole picture and deliver unprecedented insight into your overall health at the molecular level. No other company comes close to providing such a broad and in-depth analysis in engaging with patients and physicians.
Statements in this presentation about the Company's expectations, applications of its technology, markets, launch of tests and other statements that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's current beliefs, assumptions, estimates and projections. Actual results may differ materially from those projected in the forward-looking statements for various reasons, including risks associated with product and test development, test transfer to contracting labs, government regulation, market acceptance, limited commercial experience, dependence on key personnel, obtaining financing and other factors discussed in the Company's periodic reports filed with the Securities and Exchange Commission.
IRIS Biotechnologies Inc.
President and CEO
Source: IRIS Biotechnologies Inc.